By whole-exome sequencing of non–small cell lung cancers (NSCLCs) treated with a PD-1 antibody, Rizvi et al29 showed that the higher nonsynonymous mutation and higher neoantigen burden in tumors of smokers might contribute to improved response. Here, PDCD1 is linked to lung cancer.